Mashup Score: 1
TwitterThe answer here is NO. Having another option that provides no evidence of superiority but adds a year of treatment,… https://t.co/37Y0BugbHd
See more from The Fellow on Call: The Heme/Onc Podcast
Dr. Jack West of City of Hope gives his take on the presented results of the AGEAN trial looking at neoadjuvant chemo + IO followed by adjuvant IO in NSCLC. More IO may not be the answer but survival data not mature.